Sign In
Buy AIMT
$34.49
+0 (+0%)
At Close: May 27, 2022
Coronavirus begins disrupting clinical trials as companies try containing spread
03:39pm, Wednesday, 18'th Mar 2020
U.S.-based Iveric bio Inc delayed enrolment in a trial of its eye disease drug on Wednesday, two days after Provention Bio paused a study of its diabetes drug but allowed trial patients to complete th
UPDATE 2-FDA urges virtual patient visits as coronavirus disrupts clinical trials
03:37pm, Wednesday, 18'th Mar 2020
The U.S. Food and Drug Administration on Wednesday recommended switching to virt...
FDA cancels AdCom meeting for DBV’s peanut allergy patch, citing efficacy concerns
02:06pm, Wednesday, 18'th Mar 2020
An analyst called the patch "dead in the water," also noting that the ongoing Covid-19 pandemic could challenge the rollout of a competing therapy, Aimmune's Palforzia, which the FDA approved in Janua
Coronavirus begins disrupting clinical trials as companies try containing spread
02:00pm, Wednesday, 18'th Mar 2020
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as drug developers begin taking preventive measures to contain the fast-s…
UPDATE 1-Coronavirus begins disrupting clinical trials as companies try containing spread
01:59pm, Wednesday, 18'th Mar 2020
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clin...
U.S. companies begin delaying clinical trials due to coronavirus outbreak
12:52pm, Wednesday, 18'th Mar 2020
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as the drug developer said it would postpone recruitment for a trial of i…
U.S. companies begin delaying clinical trials due to coronavirus outbreak
12:51pm, Wednesday, 18'th Mar 2020
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clin...
Goldman likes McKesson in premarket analyst action
11:53am, Wednesday, 18'th Mar 2020
Osmotica Pharmaceuticals (NASDAQ:OSMT) initiated with Buy rating and $8 (74% upside) price target at SunTrust.Epizyme (NASDAQ:EPZM) added to Best Ideas List at Wedbush with a $30 (68% upside) price ta
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
11:36am, Wednesday, 18'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron P
Peanut allergy patients ready for Peninsula company's new drug as COVID-19 slows launch
02:40am, Wednesday, 18'th Mar 2020
From social distancing for patients to company representatives meeting with allergists and payers, the rollout of the drug is anything but normal.
10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades
09:13pm, Tuesday, 17'th Mar 2020
The COVID-19-induced sell-off has taken a toll on stocks across sectors. An analyst at Cantor Fitzgerald presented his take on how biotech investing could look after the coronavirus pandemic and highl
AcelRx Acquiring Tetraphase, And Other News: The Good, Bad And Ugly Of Biopharma
01:44pm, Tuesday, 17'th Mar 2020
In its latest earnings call, ACRX said it will acquire Tetraphase. AIMT reports more positive data in peanut allergy follow on study. Stemline reports results.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced eff
DBV Tech down 45% premarket on hiccup with Viaskin Peanut
12:21pm, Tuesday, 17'th Mar 2020
DBV Technologies (NASDAQ:DBVT) craters 45% premarket on increased volume in reaction to its announcement that the FDA, during its review of its marketing application for Viaskin Peanut, has identifi
Dbv technologies : Face aux interrogations des autorités américaines, DBV s'écroule en Bourse
11:00am, Tuesday, 17'th Mar 2020
(BFM Bourse) - Le parcours d'obstacle de la biotech tricolore pour essayer de faire homologuer son traitement de l'allergie à l'arachide par la FDA se …
